基于衰老视角评析肌少症实验药理模型的研究进展  

Research progress on experimental pharmacology models of sarcopenia from the view of senescence

作　　者：付勇芳 郭怡洵 王晶 李文雄 张岩[1,4] FU Yongfang;GUO Yixun;WANG Jing;LI Wenxiong;ZHANG Yan(Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Shanghai Geriatric Institute of Chinese Medicine,Shanghai 200031,China;Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712046,Shaanxi,China;Key Laboratory of Theory and Therapy of Muscles and Bones,Ministry of Education,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院,上海200032 [2]上海市中医老年医学研究所,上海200031 [3]陕西中医药大学附属医院,陕西咸阳712046 [4]教育部筋骨理论与治法重点实验室,上海200032

出　　处：《中国临床药理学与治疗学》2022年第8期892-898,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金(82074468);上海市科技创新行动计划(21400760400);上海市优秀学术带头人计划(19XD1423800)。

摘　　要：肌少症主要表现为骨骼肌质量、力量和功能的进行性下降,已经成为老年肌肉骨骼系统的主要慢性疾病之一。在基础研究中,可靠的实验模型对于深入理解肌少症的病理生理机制以及新药研发具有重要意义。本文初步总结了衰老诱导肌少症的潜在机制,并重点从体外细胞模型、体内动物模型,讨论基于衰老分子机制的肌少症药理模型的研究进展。Sarcopenia,characterized as the progressive decrease in skeletal muscle mass,strength,and function,has been becoming one of chronic musculoskeletal diseases in aging people.In basic research studies,a reliable experimental model would be vital significance for deeply understanding pathophysiological mechanism of sarcopenia and developing novel drugs.This review provided a preliminary summary on the potential mechanisms involved in senescence-induced sarcopenia,followed by a discussion on research progress on pharmacology models based on molecular mechanism of senescence,especially from in vitro cell models and in vivo animal models.

关 键 词：肌少症 衰老 药理模型 骨骼肌 

分 类 号：R337[医药卫生—人体生理学]